Physician profile
Andrew G Lee
NPI 1962403105
$257,215.56
in general payments reported to CMS, 2019-2025
34 companies · $43K in 2025
The $43K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $38.91 · 2021: $1,381 · 2022: $748 · 2023: $60K · 2024: $142K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $142K · Honoraria: $43K · Consulting Fee: $30K · Travel and Lodging: $22K · Food and Beverage: $7,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $142,155.00 |
| Honoraria | $42,522.00 |
| Consulting Fee | $29,527.50 |
| Travel and Lodging | $22,409.62 |
| Food and Beverage | $7,332.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $142,967.78 | 2024-2025 | Uplizna, Tepezza |
| Horizon Therapeutics Plc | $54,663.48 | 2019-2023 | Uplizna, Tepezza |
| Alexion Pharmaceuticals, INC. | $28,106.39 | 2021-2025 | Ultomiris, Soliris |
| Celgene Corporation | $9,450.00 | 2023 | |
| Astrazeneca Uk Limited | $5,101.50 | 2023-2024 | |
| Catalyst Pharmaceuticals, INC. | $4,830.27 | 2024-2025 | |
| Dompe Farmaceutici S.P.A. | $4,809.55 | 2025 | |
| Argenx US, INC. | $2,381.23 | 2022-2025 | Vyvgart Hytrulo |
| Astrazeneca Pharmaceuticals Lp | $2,148.00 | 2023 | |
| Biogen, INC. | $1,000.00 | 2021 | |
| Dompe US, INC. | $359.77 | 2021-2025 | Oxervate |
| Alcon Vision LLC | $274.57 | 2021-2025 | Unity, Tryptyr, Rocklatan |
| Sun Pharmaceutical Industries INC. | $181.36 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $142.40 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $140.41 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $120.42 | 2024 | Percept Pc Brainsense |
| Penumbra, INC. | $74.22 | 2024 | Penumbra Coil 400 |
| Ucb, INC. | $56.86 | 2024-2025 | Rystiggo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $54.73 | 2019-2021 | |
| Abbvie INC. | $49.35 | 2022 | |
| Stryker Corporation | $48.08 | 2025 | T2 |
| Shire North American Group INC | $42.07 | 2019 | |
| Genentech USA, INC. | $22.71 | 2024 | Vabysmo |
| Glaukos Corporation | $21.93 | 2021 | |
| Kala Pharmaceuticals, INC. | $20.36 | 2021 | |
| Genentech, INC. | $19.16 | 2021 | |
| Apellis Pharmaceuticals, INC. | $18.24 | 2023 | |
| Eyevance Pharmaceuticals LLC | $17.84 | 2020 | |
| Merz North America, INC. | $17.29 | 2019 | |
| Allergan, INC. | $16.26 | 2022 | |
| Mallinckrodt Enterprises LLC | $16.19 | 2019 | |
| Biotissue Holdings INC. | $14.81 | 2022 | |
| Oyster Point Pharma, INC. | $14.70 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $13.63 | 2024 | Tecnis Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.